This is corroborated by 2 new studies in prostate and renal cell as well as endometrial carcinoma [31,32] which propose 6H2.1 as the antibody of choice, demonstrating excellent sensitivity for both nuclear and cytoplasmic staining, specificity for PTEN immunoblot and good correlation with PTEN FISH status with regard to nuclear staining. Here, PTEN is linked to endometrial carcinoma.